• Sector: Healthcare
  • Geography: Americas
  • Stage: Late
  • Investment Year: 2007
  • Exit Year: 2013
  • Website Link

Bausch & Lomb, Inc.

In 2007, Warburg Pincus invested in Bausch & Lomb (B&L), a leading global developer, manufacturer, and marketer of ophthalmic products, including contact lenses, contact lens care solutions, cataract surgical products, and ophthalmic pharmaceuticals. The B&L brand is one of the best known and most respected ophthalmic brands with products available in over 100 countries. Following the firm’s transaction to take B&L private, Warburg Pincus assisted in assembling a world-class senior management team and Board of Directors to lead the company. Additionally, Warburg Pincus provided significant guidance in helping B&L evaluate business development opportunities, including major transactions such as the acquisition of Eyeonics, inc. and the formation of the Technolas Perfect Vision joint venture, as well as smaller asset purchases and product licensing opportunities in the vision care and pharmaceutical divisions. Furthermore, Warburg Pincus and its advisors were actively involved in helping the management team develop and implement strategies to resolve a series of contingent liabilities the company was dealing with at the time of the take-private transaction. Warburg Pincus exited the investment in 2013 through the sale of B&L to Valeant Pharmaceuticals.

Website Case Studies Disclaimer

The investments described in the case studies are provided for illustrative purposes only and are not, and do not purport to be, representative of all investments, or all types of investments, previously made by Warburg Pincus, or indicative of the performance of all prior Warburg Pincus investments. The case studies have been selected on the basis of objective criteria that Warburg Pincus believes are representative of the firm’s experience partnering with portfolio company management teams, and of the sectors, stages, strategies and/or geographies in which the firm invests. The information provided in the case studies are not necessarily an indication of future results, and may not be relied up for any purpose. Warburg Pincus’ current or future portfolio companies may differ materially in size, type, performance and other characteristics from the investments presented in the case studies. Further, references in this case study should not be construed as a recommendation or offer to buy or sell any particular security or to make any particular investment.